Logo

Merck Reports the P-IIb/III Study Data of Clesrovimab (MK-1654) to Prevent RSV Disease in Infants

Share this

Merck Reports the P-IIb/III Study Data of Clesrovimab (MK-1654) to Prevent RSV Disease in Infants

Shots:

  • Merck has reported topline data from the P-IIb/III (MK-1654-004) study assessing the safety & efficacy of clesrovimab vs PBO to prevent RSV disease among healthy preterm & full-term infants
  • The study reached its 1EP of safety & effectiveness, showing a reduction in medically attended lower respiratory infections (MALRI) due to RSV at D150. Data will form the basis of filings to regulatory authorities worldwide & will be highlighted at future conferences
  • Clesrovimab (MK-1654) is an extended half-life mAb intended for passive immunization to prevent lower respiratory infections due to RSV in infants

Ref: Merck Image: Merck

Related News:- Merck’s Capvaxive Receives the US FDA’s Accelerated Approval to Prevent Invasive Pneumococcal Disease and Pneumonia in Adults

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions